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Patients with Parkinson’s disease (PD) experience progressive neurological decline, and
future interventional therapies are thought to show most promise in early stages of the
disease.There is much interest in therapies that target the subthalamic nucleus (STN) with
surgical access. While locating STN in advanced disease patients (Hoehn–Yahr Stage III
or IV) is well understood and routinely performed at many centers in the context of deep
brain stimulation surgery, the ability to identify this nucleus in early-stage patients has not
previously been explored in a sizeable cohort. We report surgical methods used to tar-
get the STN in 15 patients with early PD (Hoehn–Yahr Stage II), using a combination of
image guided surgery, microelectrode recordings, and clinical responses to macrostimu-
lation of the region surrounding the STN. Measures of electrophysiology (firing rates and
root mean squared activity) have previously been found to be lower than in later-stage
patients, however, the patterns of electrophysiology seen and dopamimetic macrostimula-
tion effects are qualitatively similar to those seen in advanced stages. Our experience with
surgical implantation of Parkinson’s patients with minimal motor symptoms suggest that it
remains possible to accurately target the STN in early-stage PD using traditional methods.
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INTRODUCTION
Parkinson’s disease (PD) is a progressive and ultimately devastat-
ing neurological disease. Development of new therapies is ongo-
ing, and earlier stage interventions may show the most promise
of slowing down the progression of the disease. Potential early-
intervention therapies include gene transfer and deep brain stim-
ulation (DBS) (1, 2), each requiring localization and surgical
targeting of the subthalamic nucleus (STN).
Targeting of the STN using microelectrode mapping and
macrostimulation in more advanced patients has been exten-
sively performed in DBS for the treatment of advanced PD (3,
4). This widely accepted therapy is pursued when symptoms are
not adequately controlled by medications (5, 6), and is often
done later in the course of the disease (Hoehn–Yahr Stage III
and IV). In these procedures, both microelectrode recording
(MER) to identify the borders of the nucleus and macrostimu-
lation to determine symptom reduction are used to locate the
STN. There are uncertainties when applying these techniques
to patients in earlier stages for early-interventional approaches.
First, early in the course of the disease, MER characteristics
are poorly understood, due in part to the paucity of data on
the characteristics of the STN in a healthy human. Second, the
utility of macrostimulation in early stages of the disease is not
clear: in early-stage patients symptomatology is reduced and
differences may not be clinically appreciable in the operative
setting.
Thus, while locating STN in advanced disease patients is well
understood and routinely performed at many centers in the
context of DBS surgery, the ability to identify this nucleus in
early-stage patients has not previously been explored in a sizeable
cohort. Of particular surgical interest in this study was whether
electrophysiological and macrostimulation mapping techniques
established and refined in late PD populations could adequately
describe and locate the STN in an earlier stage PD patient (Hoehn–
Yahr Stage II) who will have substantially reduced symptoma-
tology. The intraoperative MER technique and results reported
here show that targeting can be successfully accomplished using
traditional methods, even in patients with limited symptoma-
tology, indicating feasibility of surgical targeting for early-stage
interventions.
MATERIALS AND METHODS
PATIENT SELECTION
The methods reported here are drawn from an ongoing pilot clini-
cal trial testing the safety and efficacy of DBS therapy in early-stage
PD at Vanderbilt University Medical Center (NCT00282152, FDA
investigational device exemption G050016). All procedures were
in accordance with the ethical standards of Vanderbilt University
Institutional Review Board (IRB approval 040797) and with the
Helsinki Declaration of 1975 (rev 1983). Between August 2006
and April 2009, 30 subjects with early-stage PD were enrolled in
a prospective, randomized, single-blind clinical trial comparing
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Table 1 | Baseline characteristics of patients [adapted with permission
from Charles et al. (7), l-DOPA equivalency based on equation from
Deusch et al. (9)].
Characteristic n=15
GENDER
Male 14
Female 1
AGE (YEARS)
Mean 60±6.8
Range 52–74
BASELINE MEDICINE USE
Mean duration (years) 2.2±1.4
Mean l-DOPA equivalents (mg/day) 451±304
BASELINE UPDRS SCORE
Mean total 39±14
Mean UPDRS-III 15±8.5
optimal drug therapy to bilateral STN stimulation plus optimal
drug therapy (1, 7). Preselection criteria were patients aged 50–75
who had been on medication between 6 and 48 months, free of
motor fluctuations such as levodopa associated dyskinesias or
unexpected “on/off” phenomena. These patients were earlier stage
than in a previous study of DBS in patients with early motor
fluctuations (8). After informed consent was obtained, patients
underwent a detailed screening evaluation to ensure their eligibil-
ity for the trial. Subjects were required to be Hoehn–Yahr Stage
II in the “off” medication state and exhibit a 30% improvement
in their UPDRS-III score between the “off” and “on” medication
states (see baseline characteristics, Table 1). The screening also
included a neuropsychological assessment, psychiatric evaluation,
and brain MRI scan to identify abnormalities that would pre-
vent the placement of DBS electrodes. Patients meeting inclusion
criteria underwent 1 week of medication washout and baseline
assessment and were randomized into two groups of 15 subjects
(optimal drug therapy vs. DBS plus optimal drug therapy). Those
randomized to receive DBS were implanted within 2 months of
their baseline assessment, data presented here.
PRESURGICAL IMAGE-BASED TARGETING
For patients randomized to the DBS group, stereotactic targeting
and electrode insertion was performed using a rapid prototyped,
miniature stereotactic system (WayPoint™ Stereotactic System;
FHC Inc., Bowdoin, ME, USA) described in detail elsewhere (10).
Preoperative MRI (standard T1 and T2 weighted) and CT imag-
ing of the brain, in combination with an assessment of AC–PC
coordinates, was used to target the dorsolateral STN (11, 12).
SURGICAL METHODS
In preparation for implantation of the DBS leads, subjects dis-
continued dopamine agonist medications at least 48 h prior to
surgery, and all other antiparkinsonian medications were dis-
continued 24 h prior to surgery (11). On the day of surgery,
patients were brought to the operating room and placed in a semi-
recumbent position. Under local anesthesia (lidocaine/marcaine)
and with minimal IV sedation (dexmedetomidine/remifentanil), a
burr hole and durotomy were performed to expose the brain sur-
face. Using the miniature, rapid prototyped frame (microTargeting
Platform™; FHC Inc., Bowdoin, ME, USA), one or two electrode
microdrives were attached to the platform. IV sedation was dis-
continued at least 20 min before microelectrode mapping to ensure
patients were alert and the STN fully responsive, fully consistent
with established practices for later-stage DBS at Vanderbilt.
INTRAOPERATIVE MAPPING AND TARGETING
Microelectrode recording was used to confirm STN location, and
to overcome any intraoperative shift in target position due to cere-
brospinal loss or edema (13–15). Arrays of 3–4 tungsten microelec-
trodes (0.3–1.0 MΩ at 1 kHz; Model 44970R; FHC Inc., Bowdoin,
ME, USA) were attached to each microdrive via guide tubes spaced
2 mm apart in a “Ben-gun” configuration (10, 11). For 11 patients,
neurophysiology was mapped using a four-channel Leadpoint
recording system (Medtronic, Inc., Minneapolis, MN, USA). These
MERs were band-pass-filtered (0.5–5 kHz), amplified, displayed,
and digitally stored (24 kHz sampling rate). For these patients the
mapping procedure was performed sequentially, first on one hemi-
sphere and then repeated for the opposite hemisphere (left brain
first in nine patients). For the remaining 4 patients, MER was
obtained using an eight-channel Guideline 4000 system (FHC,
Bowdoin, ME, USA). Signals were band-pass-filtered (0.5–5 kHz),
amplified, displayed, and digitally stored (48 kHz sampling rate).
For these patients both sides were able to be mapped simultane-
ously, a common practice at our center. Ten-second MERs were
made at regular intervals (every 0.5 mm) along a pre-defined tra-
jectory to the STN starting 10 mm above the preoperatively defined
target and finishing 5–8 mm below target, usually a few millime-
ters inferior to the dorsal border of the SNr. Recordings within
the thalamus, zona incerta (Zi), STN, and SNr were classified by
an experienced neurophysiologist. STN traces were classified using
accepted criteria, namely, increased background activity (neuronal
“hash”) and high-rate irregularly firing neurons [e.g., Ref. (3, 4)],
verified using offline analysis. Fifteen patients were randomized to
the surgery group, but one patient’s electrophysiology was irrecov-
erable for post hoc analysis, so this report reflects neurophysiology
from 14 patients.
After the MER mapping, macrostimulation mapping along
the extent of electrophysiologically identified STN was then per-
formed for all tracts under the supervision of a movement dis-
orders neurologist to characterize the stimulation thresholds for
reduction in rigidity (efficacy) and side effects (such as paresthe-
sias, muscular contraction, or eye deviation). Rigidity and tremor
were rated in a combined rating to be improved from 0 to 100%.
Stimulation side effects (e.g., paresthesias and contraction) and
affected body part (e.g., eyes and hand) were recorded. The range
of current used for the efficacy and side effect mapping was
approximately 0–5 mA, stepped by 0.5 mA.
After microelectrode mapping and macrostimulation effects
were completed for all tracts, final target selection for locating the
center of the quadripolar DBS lead (#3389; Medtronic Neuromod-
ulation, Minneapolis, MN, USA) was determined by assessing the
optimal results of three factors: MER definition of the dorsolat-
eral border of STN, intensity of stimulation needed for reduction
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in rigidity of the contralateral upper extremity, and intensity of
stimulation that resulted in undesirable side effects. The DBS lead
was implanted in the tract that produced the best efficacy upon
low threshold macrostimulation and the least side effects, where
the two middle contacts spanned the most efficacious macros-
timulation zone. Once the most favorable track and depth for
stimulation were identified, the test electrode was replaced with
a permanent DBS lead (Model 3389; Medtronic, Inc., Minneapo-
lis, MN, USA), which was tested for functionality, affixed to the
skull, coiled under the scalp, and prepared for connection to
bilateral implantable pulse generators (IPG, Model 7426 Soletra
Neurostimulator; Medtronic, Inc., Minneapolis, MN, USA) dur-
ing a follow-up procedure within 10 days. The average location of
the centroid of the lead was 10.7 mm lateral, 1.1 mm posterior, and
3 mm inferior to the mid-commissural point [see Ref. (11)]. Other
than a longer time for medicine to be discontinued presurgery [see
Ref. (5)], the details of this procedure do not differ significantly
from the procedure used for DBS-implantation in later-stage PD
patients at this center (10).
OFFLINE MICROELECTRODE RECORDING ANALYSES
In-house MATLAB scripts (MathWorks Inc., Natick, MA, USA)
were used to calculate all electrophysiological measures; these
were verified by Neuroexplorer 4 (Nex Technologies, Littleton,
MA, USA) analyses. Tracks with <1.5 mm of STN recordings
were excluded from analysis. Individual units were sorted from
background using standard spike-sorting methods including auto-
mated cluster analysis of principal components (Spike Sorter v2.8,
Plexon Inc., Dallas, TX, USA). As an aggregate and robust measure
of neural activity, root mean square (RMS) measures of voltage
were calculated from raw, unsorted data. For firing rate mea-
sures,only demonstrable single units were included in this analysis;
poorly isolated units and multiple units with overlapping clusters
in 2D PC space (MANCOVA p> 0.05) were excluded from further
analysis.
RESULTS
Here we report the targeting and mapping procedure from DBS
lead implantation in 15 patients with early PD. All subjects are
Caucasian (one female), and the baseline UPDRS (part III) scores
demonstrate only very mild symptomatology (see Table 1 for
detailed description). Image-based targeting using preoperative
CT and MRI allowed for approximate localization of the STN in
each patient (Figure 1).
Electrophysiology recorded during surgery revealed that at least
one electrode track per hemisphere contained electrophysiologi-
cally identifiable STN (range: 1–4 per hemisphere). In total, 68
tracts that contained at least 1.5 mm of STN were identified in
28 hemispheres. In Figure 2, an exemplar pass of electrophysi-
ological traces by structure is shown. These traces were similar
to what is encountered in later-stage DBS surgery [see Ref. (3)].
Specifically, in a typical pass, we found that thalamic activity was
characterized by low baseline activity, with well isolated action
potentials. The Zi was characterized by sparse neural activity,
but when cells were encountered, they had tonic firing patterns
with high amplitude action potentials, well isolated from back-
ground. The STN, even in early Parkinson’s disease patients, was
characterized by high baseline neuronal activity, with isolated
neurons having high frequency and irregular firing rates. Even
though these action potentials were also high amplitude, their rel-
ative amplitudes relative to baseline were lower than surrounding
structures, a characteristic of STN. After 1–2 mm of low activity
quiet zone, corresponding to white matter tracts, the substantia
nigra (pars reticulata; SNr) was commonly encountered, a struc-
ture that exhibited high firing rates, with well isolated action
potentials on top of relatively low baseline activity. Indeed, this
pattern of results is confirmed when plotting RMS of voltage
with depth, a measure easily accessible intraoperatively (Figure 3).
Of note is the strong increase in RMS along the extent that was
identified as STN (dotted lines).
To quantitatively describe the electrophysiological activity of
the STN in these patients, Figure 4 (upper panel) shows the dis-
tribution of average RMS activity for all STN tracts across all
hemispheres and patients. The mean RMS of 13.2 mV is indi-
cated by a dotted line. A subset of this data was presented in an
earlier report (17), and for ease of comparison the figures follow
their conventions. Figure 4 (lower panel) shows the distribution
of firing rates for all identified single units (n= 210) in STN from
13 hemispheres. Mean firing rate is 27.7 sp/s, indicated by the dot-
ted line. These values are consistent with the earlier report and are
lower than values of those later-stage patients.
After the dorsoventral extent of the STN was determined, effi-
cacy and side effect profile of all electrode tracts was assayed
through macrostimulation mapping. From 1 to 2 mm above the
STN to the bottom of STN (where limiting side effects were elicited
at very low currents), stimulation effects were determined, where
the range of current was from 0 to 4 mA, stepped by approximately
0.5 mA. Rigidity and tremor improved from 0 to 100% (com-
bined rating, see Materials and Methods) at thresholds from 0.5
to 4 mA. Stimulation side effects included facial and hand pares-
thesia, dysarthria, and gaze preference at thresholds from 1 to
4 mA.
FIGURE 1 | Preoperative image guided targeting of left STN for one
subject. White line is the trajectory, shown on top of a coronal section at
level of target, at bottom of line (actual tract is paracoronal). Image is T1
contrast weighted, neurological conventions where left is on image right.
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FIGURE 2 | Electrophysiological traces taken along a trajectory to and
though the STN from a mapping pass of a single tract in early PD (one
of four tracts). Ten-second long traces were taken but for ease of
visualization of detail, the first 5 s are shown.Y -axes scaled identically to
bottom panel. These traces are typical of what is encountered when
passing from thalamus to Zi through STN to substantia nigra (pars
reticulata). Note that the qualitative activity along the pass is not different
from what is encountered when targeting during later-stage PD [e.g., Ref.
(3)]. Pass superimposed on a sagittal schematic adapted from
Schaltenbrand and Wharen (16).
FIGURE 3 |Typical RMS by depth. Note the strong increase in RMS along
the extent that was identified as STN (dotted lines). In early PD, an increase
in RMS is an indicator of STN location, much as it is in later stages. Zero
indicates the level of target from preoperative plan. These data are derived
from pass reflected in Figure 1.
Perioperative events are summarized in Table 2. Perioperative
adverse events for this trial are similar to those already reported to
be associated with DBS therapy for PD. One subject experienced
a stroke, causing persistent but mild cognitive impairment and
weakness in the right face and arm, which subsequently resolved
over several months. This was the only perioperative event lasting
FIGURE 4 | Distributions of root mean square power (RMS, upper
panel) for each STN pass and firing rates (lower panel) for all STN
neurons. Mean values are indicated by the dotted line.
longer than 3 months; the remaining 14 subjects experienced
only typical post-operative discomfort and mild transient adverse
effects that resolved in the 3-month perioperative period.
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Table 2 | Perioperative adverse events, n=56 [adapted with
permission from Kahn et al. (11)].
Type of adverse event Transient Ongoing
RELATEDTO PROCEDURE OR DEVICE
Wound healing problems 10 0
Erythema 2 0
Edema 2 0
Pain 2 0
Drainage 2 0
Tingling 0 1
Tenderness 1 0
Headache 5 0
Edema 4 0
Scalp 2 0
Facial 2 0
Confusion 4 0
Imbalance 3 0
Drowsiness 2 0
Nausea 2 0
Vomiting 2 0
Expressive aphasia 2 0
Neck problems 2 0
Pain 1 0
Stiffness 1 0
Throat problems 2 0
Pain 1 0
Edema 1 0
Aborted procedure 2 0
Hematoma 1 0
Dysphagia 1 0
Intracranial edema 1 0
Basal ganglia infarct 0 1
Extremity weakness 1 0
Hallucination 1 0
Urinary retention 1 0
Constipation 0 1
Rigidity 1 0
Divergent gaze 1 0
Apnea 1 0
RELATEDTO STUDY
Syncope 1 0
NOT RELATEDTO STUDY
Incidental CT imaging sinus findings 0 4
Paresthesias 1 0
Fever 1 0
Chest soreness 1 0
The “ongoing” column indicates any symptoms lasting longer than 3months.
DISCUSSION
Here we report targeting of the STN and surrounding structures
in an ongoing prospective trial testing STN-DBS in patients with
early-stage PD. The results reported here suggest that the careful
application of accepted surgical methods including image guided
targeting, microelectrode mapping, and macrostimulation can be
used to successfully target the STN in DBS-implantation proce-
dures for early-stage PD, even in patients with minimal sympto-
matology. Consistent for all traces recorded from these patients,
the qualitative activity along the pass is not different from what
is commonly encountered when targeting the STN during later-
stage PD (3, 4). In previous studies of a subset of these patients, the
measured STN firing rates and RMS have been found to be slightly
lower than in later-stage PD patients (17), presenting a potential
difficulty for surgical targeting. However, in this paper we report
the changes from the white matter and surrounding structures are
still sufficiently robust enough for accurate targeting. In early PD,
much as it does in later stages, an increase in global neural activity
measures (RMS) is an indicator of STN location, much as it is
in later-stage PD. Though more research is needed, this increase
in STN activity is most likely due to disease progression rather
than age per se. Strikingly, even with mild symptoms associated
with early stages of the disease, dopamimetic effects of stimula-
tion could still be elicited to confirm the most efficacious portion
of the STN.
While presenting the targeting methods used at this center,
these data also provide a foundation upon which future clini-
cal trials can be designed for early-intervention therapies. One
limitation of comparing data from multiple centers is that DBS-
implantation centers utilize many different techniques for intraop-
erative recordings when attempting to identify the optimal target
for implantation. Toward this end, this reports a detailed descrip-
tion of both the intraoperative technique for data collection, as
well as the method for recording analysis leading to our findings.
These subjects demonstrate a robust physiology that allowed tradi-
tional MER and stimulation techniques to be used in the effective
surgical targeting of the STN, indicating feasibility of the surgical
approach in proposed early-stage interventions targeting the STN
(1, 2), which require surgical targeting of the STN. As surgical
techniques are improved and risks reduced, is hoped that early-
interventional therapies, including those targeting the STN, show
promise in slowing the progressive motor and cognitive decline
in PD.
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